US20040028752A1 - Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker - Google Patents

Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker Download PDF

Info

Publication number
US20040028752A1
US20040028752A1 US10/214,333 US21433302A US2004028752A1 US 20040028752 A1 US20040028752 A1 US 20040028752A1 US 21433302 A US21433302 A US 21433302A US 2004028752 A1 US2004028752 A1 US 2004028752A1
Authority
US
United States
Prior art keywords
accordance
calcium channel
nitric oxide
channel blocker
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/214,333
Other languages
English (en)
Inventor
Michael Kamm
Robin Phillips
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SLA Pharma AG
Original Assignee
SLA Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32475044&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20040028752(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9703750.1A external-priority patent/GB9703750D0/en
Priority to GBGB9703750.1A priority Critical patent/GB9703750D0/en
Priority to GBGB9727238.9A priority patent/GB9727238D0/en
Priority claimed from GBGB9727238.9A external-priority patent/GB9727238D0/en
Priority to DE69826644T priority patent/DE69826644T2/de
Priority to JP53641998A priority patent/JP3352095B2/ja
Priority to ES98907038T priority patent/ES2224362T3/es
Priority to PCT/GB1998/000575 priority patent/WO1998036733A2/en
Priority to EP98907038A priority patent/EP0969813B1/en
Priority to AT98907038T priority patent/ATE277596T1/de
Priority to DK98907038T priority patent/DK0969813T3/da
Priority to EP20020015320 priority patent/EP1249238A3/en
Priority to CNA031411657A priority patent/CN1480139A/zh
Priority to IL13147798A priority patent/IL131477A0/xx
Priority to EP02015319A priority patent/EP1250927A3/en
Priority to CA002281755A priority patent/CA2281755C/en
Priority to PT98907038T priority patent/PT969813E/pt
Priority to CNB031409091A priority patent/CN100379423C/zh
Priority to AU63024/98A priority patent/AU733047C/en
Priority to CN98802787A priority patent/CN1127333C/zh
Priority to JP2002159560A priority patent/JP2002356425A/ja
Priority to JP2002159559A priority patent/JP2002356422A/ja
Priority to US10/214,333 priority patent/US20040028752A1/en
Application filed by SLA Pharma AG filed Critical SLA Pharma AG
Publication of US20040028752A1 publication Critical patent/US20040028752A1/en
Priority to IL178133A priority patent/IL178133A0/en
Assigned to S.L.A. PHARMA AG reassignment S.L.A. PHARMA AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KAMM, MICHAEL A., PHILLIPS, ROBIN K.S.
Priority to US13/178,567 priority patent/US8318721B2/en
Priority to US13/685,023 priority patent/US8906903B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids

Definitions

  • This invention relates to the use of a calcium channel blocker or a cholinegic agent, particularly diltiazem and bethanechol, alone and in combination for the treatment of benign anal diseases where there is an associated anal sphincter spasm.
  • the invention particularly relates to the treatment of anal fissures and painful haemorrhoidal conditions.
  • a fissure is a split in the skin of the distal anal canal. It is a common complaint in young adults with a roughly equal incidence in both sexes. Acute fissures are very common and most heal spontaneously, but a proportion progress to form a chronic linear ulcer in the anal canal and show great reluctance to heal without intervention.
  • Anal dilators have also been involved in treatment. Typically a dilator of medium size was coated with anaesthetic jelly and inserted into the anal canal before the passage of stool to prevent exacerbation of the symptoms during defecation. The procedure was inconvenient and success rate was low. The most common treatment, for chronic anal fissures is a lateral internal sphincterotomy, which involves surgery to the internal anal sphincter. This procedure, however, requires hospitalisation and leads in a sizeable number of patients to impairment of continence (British Journal of Surgery 1996, 83, 1334-1344). As yet there is no proven non-surgical treatment for chronic fissure, although local injection of botulinum A toxin shows early promise (Martindale, The Extra Pharmacopoeia 31st Edition p1516 and 1517).
  • a further potential non-surgical treatment that has recently been reported for anal fissures and haemorrhoids is the topical use of a nitric oxide donor, particularly glyceryl trinitrate. This reduces the internal anal resting pressure (British Journal of Surgery, 1994, 81, 1386-1389 and British Journal of Surgery, 1996, 83, 771-775 both by present inventors; Diseases of the Colon and Rectum, May 1995, p453-457, The New England Journal of Medicine Oct. 26, 1995, p1156 and 1157, WO 95/32715 and its equivalent U.S. Pat. No. 5,504,117—all by Gorfine; British Journal of Surgery 1996, 83, 776-777).
  • Haemorrhoids are venous swellings of the tissues around the anus. Those above the dentate line (the point where the modified skin of the outer anal canal becomes gut epithelium), which usually protrude into the anal canal, are termed internal haemorrhoids, while those below this point are called external haemorrhoids. Due to internal pressure, internal haemorrhoids tend to congest, bleed and eventually prolapse; with external haemorrhoids painful thrombosis may develop.
  • a range of mainly topical drug treatments is available for symptomatic relief, but in many cases their value is a best unproven.
  • Local anaesthetics may be included to relieve pain, and corticosteroids may be used when infection is not present.
  • Preparations containing either group of drugs are intended only for short-term use.
  • Some preparations include heparinoids and other agents frequently included for their soothing properties include various bismuth salts, zinc oxide, hamamelis, resorcinol and peru balsam.
  • Diltiazem is indicated orally for the treatment of angina pectoris and hypertension, and may be given intravenously in the treatment of arterial fibrillation or flutter and paroxysmal supraventricular tachycardia.
  • Bethanechol is used as an alternative to catheterisation in the treatment of urinary retention, gastric atony and retention, abdominal distension following surgery, congenital megacolon, and oesophageal reflux. It is given in doses of 5 mg subcutaneously or 10 to 50 mg by mouth (Martindale, The Extra Pharmacopoeia, 31st Edition, p857 and p1417).
  • anal fissures and haemorrhoids and other benign anal disorders can be treated by local application to the anus of a cholinergic agent or a calcium channel blocker or a mixture thereof.
  • Other benign anal disorders would be those conditions associated with a high anal pressure or where there is an associated anal sphincter spasm.
  • a cholinergic agent or a calcium channel blocker in the preparation of a medicament for local application to the anus for the treatment or prophylaxis of benign anal disorders.
  • a second aspect of the invention provides a composition adapted for local application to the anus comprising at least one of a cholinergic agent or a calcium channel blocker together with a pharmaceutically acceptable carrier.
  • local application to the anus we mean to include local injection into the anal sphincter, and administration in and around the anal canal, preferably by topical application such as spreading a topical composition in and around the anal canal.
  • the cholinergic agents and calcium channel blockers are at least partially effective (and there may be other mechanisms of action) by lowering the anal resting pressure of the patient. This helps the fissures to heal. This reduction in anal pressure should also allow better venous drainage which will allow the haemorroidal vascular cushions to heal.
  • haemorrhoids it is also thought that the cholinergic agents will act to contract the longitudinal muscle of the anus, thereby pulling the haemorrhoidal cushions back into place.
  • anal fissures we mean to include both acute and chronic fissures or ulcers. Any patient with persistent symptoms for more than two weeks is taken to have a chronic fissure in accordance with the invention.
  • haemorrhoids we mean to include both internal and external haemorrhoids and acute thrombosis of external haemorrhoid (TEM).
  • Suitable cholinergic agents in accordance with the invention are selected from a cholinergic agonist of acetylcholine, bethanechol, carbachol, methacholine, and pilocarpine, or an anticholinesterase of ambenonium, neostigmine, physostigmine, pyridostigmine, dyflos, and ecothinopate, and pharmaceutically acceptable salts of thereof.
  • Bethanechol and salts thereof is a particularly preferred cholinergic agent.
  • Suitable calcium channel blockers in accordance with the invention are selected from amlodipine, anipamil, barnidipine, benidipine, bepridil, darodipine, diltiazem, efonidipine, felodipine, isradipine, lacidipine, lercanidipine, lidoflazine, manidipine, mepirodipine, nicardipine, nifedipine, niludipine, nilvadipine, nimodipine, nisoldipine, nitrendipine, perhexiline, tiapamil, verapamil, and pharmaceutically acceptable salts thereof.
  • Diltiazem and salts thereof is a particularly preferred calcium channel blocker.
  • a further preferred aspect of the invention provides a composition for local application to the anus, particularly topically acting composition, but not exclusively for topical application in and around the anal canal comprising diltiazem or bethanechol or a combination thereof or pharmaceutically acceptable salts thereof, together with a pharmaceutically acceptable carrier.
  • diltiazem or bethanechol or a combination thereof and pharmaceutically acceptable salts thereof in the preparation of a topical medicament for the treatment or prophylaxis of benign anal disorders, particularly in the treatment of anal fissures and haemorrhoids.
  • salts of the aforementioned agents include those formed with both organic and inorganic acids.
  • Such acid addition salts will normally be pharmaceutically acceptable although salts of non-pharmaceutically acceptable salts may be of utility in the preparation and purification of the compound in question.
  • preferred salts include those formed from hydrochloric, hydrobromic, sulphuric, citric, tartaric, phosphoric, lactic, pyruvic, acetic, succinic, oxalic, fumaric, maleic, oxaloacetic, methanesulphonic, ethanesulphonic, benzenesulphonic, and isethionic acids.
  • Salts of the compounds of formula (1) can be made by reacting the appropriate compound in the form of the free base with the appropriate acid. Salts of halides are also suitable. Diltiazem hydrochloride, diltiazem malate and diltiazem have CAS registry numbers respectively as follows: 33286-22-5, 144604-00-2, and 42399-41-7. Bethanechol and bethanechol chloride have CAS registry numbers respectively of 674-38-4 and 590-63-6.
  • Diltiazem and bethanechol are of great benefit when topically administered separately, but are of particular benefit and apparently exhibit a synergistic activity when administered together.
  • a suitable proportion of calcium channel blocker, such as diltiazem in a topical or local composition for a beneficial effect is at least 0.5% w/w, such as 0.5% to 10% w/w, preferably 0.5% to 5% w/w, more preferably still 1% to 5% w/w, still more preferably 1% to 3%, and most preferably about 2% w/w.
  • Preliminary dose ranging studies suggest that the maximum effect of the invention is obtained at about 2% and thereafter higher concentrations will not produce a substantial additional effect.
  • the diltiazem composition is suitably applied 3 to 6 times, preferably 3 to 4 times daily, which based on 8 mg per application, gives a total daily dose of 24 mg to 48 mg.
  • a suitable proportion of cholinergic agent, such as bethanechol in a topical or local composition is at least 0.01% w/w, more preferably at least 0.05% such as 0.01% to 3% w/w, preferably 0.01% to 1% w/w, more preferably 0.05% to 1% w/w, and most preferably about 0.1% w/w.
  • Preliminary dose ranging studies suggest that 0.1% w/w produced the maximum effect of the invention, and thereafter higher concentrations will not produce an additional effect.
  • the bethanechol composition is suitably applied in the same periodin as above which based on 0.4 mg per application, gives a total daily dose of 1.2 mg to 2.4 mg.
  • compositions adapted for topical administration in and/or around the anal canal may be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, foam, oils, aerosols, suppositories or enemas.
  • the topical compositions can comprise emulsifiers, preservatives, buffering agents and anti-oxidants.
  • the compositions also comprise steroids (e.g. present at 0.1 to 5% w/w) such as prednisolone, busenonide or hydrocortisone, locally acting anaesthetics such as lignocaine (e.g. at 0.1 to 5% w/w), and soothants.
  • steroids e.g. present at 0.1 to 5% w/w
  • anaesthetics such as lignocaine (e.g. at 0.1 to 5% w/w)
  • lignocaine e.g. at 0.1 to 5% w/w
  • Typical components used in existing fissure or haemorrhoidal treatments which can also be used in topical compositions of the invention include: zinc oxide, benzyl benzoate, bismuth oxide, bismuth subgallate and Peru balsam.
  • the cholinergic agent or calcium channel blocker can be administered in combination with trinitroglycerine or any other nitric oxide donor, isoprenaline, histamine, prostaglandin E 2 , adenosine triphosphate, nictotine, DMPP, bradykinin, caerulein, glucagon, and phentolamine.
  • the topical composition may comprise skin penetrating agents, particularly the sulphoxides, such as dimethyl sulphoxide (DMSO) preferably at 25% to 50% w/w.
  • DMSO dimethyl sulphoxide
  • Amides, (DMA, DMF) pyrrolidones, organic solvents, laurocaprom (AZONE) and calcium thioglycollate are suitable alternative penetrants.
  • the composition may also optionally contains a polyacrylic acid derivative, more particularly a carbomer. This would both act as a skin hydrating agent to aid penetration of the drug, but also an emulsifying agent. The carbomer will help emulsify the DMSO, thereby mitigating skin irritation and providing enhanced skin hydration.
  • Propylene glycol may also be present in the composition to soften the skin, increase thermodynamic potential and aid skin penetration by the DMSO and thus the drug.
  • the final pH of the composition is advantageously pH 3.5 to 4.5.
  • a method for the treatment or prophylaxis of a benign anal disorder comprising local application to the anus or the internal anal sphincter at least one of a cholinergic agent or calcium channel blocker.
  • An anal fissure and haemorroidal topical composition comprising at least one of a cholinergic agent or calcium channel blocker, together with a pharmaceutically acceptable carrier.
  • DMSO cream in the clinical studies may also have a therapeutic effect independent of the bethanechol or diltiazem.
  • a yet further aspect of the invention provides use of DMSO as a therapeutically active agent in the preparation of a topical medicament for the treatment of benign anal disorders, particularly anal fissure or haemorrhoids.
  • the DMSO is present at 25% to 50% w/w, and is advantageously present in combination with propylene glycol, preferably in a ratio by w/w of 5:1 to 15:1.
  • the DMSO composition of this further aspect of the invention is also advantageously present with a polyacrylic acid derivative, such as carbomer, preferably at a ratio by w/w of 20:1 to 80:1.
  • the pH of the composition is pH 3.5 to 4.5.
  • FIG. 1 is a graph of the dose response of diltiazem gel against mean anal resting pressure
  • FIG. 2 is a graph of duration of action of 1% w/w diltiazem gel against mean anal resting pressure
  • FIG. 3 is a graph of the dose response of bethanechol gel against mean anal resting pressure
  • FIG. 4 is a graph of duration of action of 0.1% w/w bethanechol gel against mean anal resting anal pressure
  • FIG. 5 is a graph comparing 2% diltiazem, 0.1% bethanechol, and a combination of both over time against the reduction in mean anal resting pressure.
  • a composition of base gel had the following composition: carmellose sodium 6 g, polyethylene glycol 30 ml, methylhydroxybenzoate 150 mg, propylhydroxybenzoate 15 mg, made up to volume with distilled water (pH6-7).
  • a base cream of the invention had the following composition: Diltiazem hydrochloride (2% w/w) 10 g Dimethyl sulphoxide 250 g Carbomer 974P 5 g White soft paraffin 15 g Cetomacrogel emulsifying ointment* 115 g Propylene glycol 23 g Methylhydroxybenzoate (preservative soln) to 500 g
  • a base cream was formed by firstly separate mixing of the aqueous and non-aqueous components of the cream. Weighed quantities of propylene glycol and a proportion of the preservative solution were placed in a beaker to which the weight quantity of carbomer powder was added using an impeller type mixer to form a colloidal suspension of the carbomer. Thereafter, the weighed quantity of DMSO was added and rapid stirring continued at room temperature until a translucent uniform gel had been formed.
  • the drug is then added to the remainder of the preservative solution , which in turn was then added to the gel and whilst vigorously stirring, the uniform base (above) was added to form a cream.
  • the carbomer acted as a dual neutralisation agent and primary emulsifier (of the oil and aqueous phases) to form the uniform cream base.
  • a bethanechol cream composition was made up as above, but using 0.5 g of bethanechol (0.1% w/w) instead of diltiazem.
  • 2% diltiazem cream from example 2 was applied to the anus three times daily for 8 weeks to treat patients suffering from chronic anal fissures (in an uncontrolled, open, pilot study). To date, 7 patients were studied and followed up between 2 to 5 weeks. 5 patients have had complete resolution of symptoms, of whom 3 have complete and 2 partial healing of the fissure. In four of these 5 patients there has been a reduction of the maximum resting anal sphincter pressure to within normal limits. The last patient, though symptom free, continues to have a high anal resting pressure.
  • the results show that local application to the anus of at least one of a cholinergic agent or calcium channel provides a efficacious treatment for benign anal disorder, particularly anal fissures and haemorrhoids. Furthermore since efficacy can be obtained at surprisingly low doses, the treatment of the invention is also substantially free of side effects normally associated with the active agents.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
US10/214,333 1997-02-24 2002-08-08 Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker Abandoned US20040028752A1 (en)

Priority Applications (24)

Application Number Priority Date Filing Date Title
GBGB9703750.1A GB9703750D0 (en) 1997-02-24 1997-02-24 Treatment of haemorrhoids
GBGB9727238.9A GB9727238D0 (en) 1997-12-23 1997-12-23 Pharmaceutical composition
IL13147798A IL131477A0 (en) 1997-02-24 1998-02-23 Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker
AU63024/98A AU733047C (en) 1997-02-24 1998-02-23 Pharmaceutical composition
CN98802787A CN1127333C (zh) 1997-02-24 1998-02-23 含有胆碱能药物或钙通道阻滞剂的局部用医药组合物
CNB031409091A CN100379423C (zh) 1997-02-24 1998-02-23 含有胆碱能药物或钙通道阻滞剂的局部用医药组合物
ES98907038T ES2224362T3 (es) 1997-02-24 1998-02-23 Composicon farmaceutica topica que comprende un agente colinergico o un bloqueador del canal del calcio.
PCT/GB1998/000575 WO1998036733A2 (en) 1997-02-24 1998-02-23 Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker
EP98907038A EP0969813B1 (en) 1997-02-24 1998-02-23 Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker
AT98907038T ATE277596T1 (de) 1997-02-24 1998-02-23 Topische pharmazeutische zusammensetzung, enthaltend einen cholinergischen wirkstoff oder einen kalziumkanalblocker
DK98907038T DK0969813T3 (da) 1997-02-24 1998-02-23 Topisk farmaceutisk sammensætning omfattende et kolinergt middel eller et calciumkanalblokerende middel
EP20020015320 EP1249238A3 (en) 1997-02-24 1998-02-23 Topical pharmaceutical composition comprising bethanechol
CNA031411657A CN1480139A (zh) 1997-02-24 1998-02-23 含有胆碱能药物或钙通道阻滞剂的局部用医药组合物
DE69826644T DE69826644T2 (de) 1997-02-24 1998-02-23 Topische pharmazeutische zusammensetzung, enthaltend einen cholinergischen wirkstoff oder einen kalziumkanalblocker
EP02015319A EP1250927A3 (en) 1997-02-24 1998-02-23 Pharmaceutical composition for topical application comprising nifedipine
CA002281755A CA2281755C (en) 1997-02-24 1998-02-23 Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker
PT98907038T PT969813E (pt) 1997-02-24 1998-02-23 Composicao farmaceutica topica compreendendo um agente colinergico ou um bloqueador de canal de calcio
JP53641998A JP3352095B2 (ja) 1997-02-24 1998-02-23 コリン作用剤またはカルシウムチャンネル遮断薬を含む局所用薬学的組成物
JP2002159559A JP2002356422A (ja) 1997-02-24 2002-05-31 ベタネコールを含んで成る局所用医薬組成物
JP2002159560A JP2002356425A (ja) 1997-02-24 2002-05-31 ニフェジピンを単独で又は選択的にベタネコールと組み合わせて含んで成る局所用医薬組成物
US10/214,333 US20040028752A1 (en) 1997-02-24 2002-08-08 Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker
IL178133A IL178133A0 (en) 1997-02-24 2006-09-17 Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker
US13/178,567 US8318721B2 (en) 1997-02-24 2011-07-08 Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker
US13/685,023 US8906903B2 (en) 1997-02-24 2012-11-26 Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9703750.1A GB9703750D0 (en) 1997-02-24 1997-02-24 Treatment of haemorrhoids
GBGB9727238.9A GB9727238D0 (en) 1997-12-23 1997-12-23 Pharmaceutical composition
US10/214,333 US20040028752A1 (en) 1997-02-24 2002-08-08 Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker

Publications (1)

Publication Number Publication Date
US20040028752A1 true US20040028752A1 (en) 2004-02-12

Family

ID=32475044

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/214,333 Abandoned US20040028752A1 (en) 1997-02-24 2002-08-08 Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker
US13/178,567 Expired - Fee Related US8318721B2 (en) 1997-02-24 2011-07-08 Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker
US13/685,023 Expired - Fee Related US8906903B2 (en) 1997-02-24 2012-11-26 Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker

Family Applications After (2)

Application Number Title Priority Date Filing Date
US13/178,567 Expired - Fee Related US8318721B2 (en) 1997-02-24 2011-07-08 Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker
US13/685,023 Expired - Fee Related US8906903B2 (en) 1997-02-24 2012-11-26 Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker

Country Status (13)

Country Link
US (3) US20040028752A1 (ja)
EP (3) EP1250927A3 (ja)
JP (3) JP3352095B2 (ja)
CN (3) CN1480139A (ja)
AT (1) ATE277596T1 (ja)
AU (1) AU733047C (ja)
CA (1) CA2281755C (ja)
DE (1) DE69826644T2 (ja)
DK (1) DK0969813T3 (ja)
ES (1) ES2224362T3 (ja)
IL (2) IL131477A0 (ja)
PT (1) PT969813E (ja)
WO (1) WO1998036733A2 (ja)

Cited By (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060018937A1 (en) * 2002-10-25 2006-01-26 Foamix Ltd. Steroid kit and foamable composition and uses thereof
US20060233721A1 (en) * 2002-10-25 2006-10-19 Foamix Ltd. Foam containing unique oil globules
US20060275218A1 (en) * 2003-08-04 2006-12-07 Foamix Ltd. Foamable vehicle and pharmaceutical compositions thereof
US20070253911A1 (en) * 2002-10-25 2007-11-01 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US20070280891A1 (en) * 2003-08-04 2007-12-06 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US20080152596A1 (en) * 2005-07-19 2008-06-26 Foamix Ltd. Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof
US20080206155A1 (en) * 2006-11-14 2008-08-28 Foamix Ltd. Stable non-alcoholic foamable pharmaceutical emulsion compositions with an unctuous emollient and their uses
US20080206159A1 (en) * 2003-08-04 2008-08-28 Foamix Ltd. Compositions with modulating agents
US20080292560A1 (en) * 2007-01-12 2008-11-27 Dov Tamarkin Silicone in glycol pharmaceutical and cosmetic compositions with accommodating agent
US20080317679A1 (en) * 2002-10-25 2008-12-25 Foamix Ltd. Foamable compositions and kits comprising one or more of a channel agent, a cholinergic agent, a nitric oxide donor, and related agents and their uses
US20100010052A1 (en) * 2006-09-01 2010-01-14 Moberg Derma Ab Topical composition comprising a dihydropyridine calcium antagonist
US20100179151A1 (en) * 2006-08-16 2010-07-15 Bayer Animal Health Gmbh Transdermal application of triazines for controlling infections with coccidia
US20100221195A1 (en) * 2006-11-14 2010-09-02 Foamix Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US20110212033A1 (en) * 2007-12-07 2011-09-01 Foamix Ltd. Oil and liquid silicone foamable carriers and formulations
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US8119106B2 (en) 2003-04-28 2012-02-21 Foamix Ltd Foamable iodine compositions
US8435498B2 (en) 2002-10-25 2013-05-07 Foamix Ltd. Penetrating pharmaceutical foam
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
US8518376B2 (en) 2007-12-07 2013-08-27 Foamix Ltd. Oil-based foamable carriers and formulations
US8618081B2 (en) 2009-10-02 2013-12-31 Foamix Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US8709385B2 (en) 2008-01-14 2014-04-29 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
US8722021B2 (en) 2002-10-25 2014-05-13 Foamix Ltd. Foamable carriers
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US9072667B2 (en) 2009-07-29 2015-07-07 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US9167813B2 (en) 2009-07-29 2015-10-27 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9320705B2 (en) 2002-10-25 2016-04-26 Foamix Pharmaceuticals Ltd. Sensation modifying topical composition foam
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
US9539208B2 (en) 2002-10-25 2017-01-10 Foamix Pharmaceuticals Ltd. Foam prepared from nanoemulsions and uses
US9622947B2 (en) 2002-10-25 2017-04-18 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US9700549B2 (en) 2013-10-03 2017-07-11 David Wise Compositions and methods for treating pelvic pain and other conditions
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US9884017B2 (en) 2009-04-28 2018-02-06 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
RU2710742C1 (ru) * 2019-05-14 2020-01-10 Александра Александровна Савосина Композиция для лечения анальных трещин на основе фелодипина
WO2021118400A1 (ru) 2019-12-13 2021-06-17 Александр Евгеньевич БАРАННИКОВ Фармакологическая композиция для лечения проктологических заболеваний (варианты)
US11766428B2 (en) 2018-06-01 2023-09-26 Tavanta Therapeutics Hungary Incorporated Topical amlodipine salts for the treatment of anorectal diseases

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1051972E (pt) 1994-05-27 2007-12-07 Strakan Internat Ltd Uma Socie Composição dadora de óxido nítrico para tratamento de distúrbios anais
CN100364540C (zh) * 2006-03-14 2008-01-30 北京大学 (2s-顺)-(+)-2,3-二氢-3-羟基-2-(4-甲氧苯基)-1,5-苯并硫氮杂䓬-4(5h)-酮在制备治疗肝炎的药物中的用途
ES2394375T3 (es) 2006-11-24 2013-01-31 Novartis Ag Composición para repeler y ahuyentar plagas
PT2498771E (pt) * 2009-11-12 2014-01-30 Acacia Pharma Ltd Uso do betanecol para o tratamento de xerostomia
GB201107533D0 (en) * 2011-05-06 2011-06-22 Acacia Pharma Ltd Formulaiton
BR112014028610A2 (pt) * 2012-05-17 2017-06-27 Contract Pharmaceuticals Ltd formulações de vesícula não iônica de bloqueadores de canal de cálcio
WO2014127475A1 (en) * 2013-02-19 2014-08-28 Hochman David Jonathan Therapeutic composition for the treatment perianal disorders
RU2592366C2 (ru) * 2013-07-22 2016-07-20 Общество с ограниченной ответственностью "ХИЛИНГ ФАРМ" Фармакологическая композиция для лечения проктологических заболеваний (варианты)
TR201710576A2 (tr) * 2017-07-19 2019-02-21 Dokuz Eyluel Ueniversitesi Rektoerluegue Mi̇kroparti̇küler si̇stem i̇çeren anal fi̇ssür tedavi̇si̇ i̇çi̇n bi̇r tampon
BR102018008324A2 (pt) 2018-04-25 2019-11-05 Laboratorios Ferring Ltda composição farmacêutica de uso tópico e processo de fabricação de composição farmacêutica de uso tópico
CN115337258A (zh) * 2022-07-22 2022-11-15 上海奥全生物医药科技有限公司 一种盐酸地尔硫卓的药物组合物、制备方法及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084281A (en) * 1989-02-14 1992-01-28 Dillon Richard S Method and solution for treating tissue wounds
US5162315A (en) * 1989-05-08 1992-11-10 Rajadhyaksha Vithal J Penetration enhancers
US5288505A (en) * 1991-06-26 1994-02-22 Galephar P.R., Inc., Ltd. Extended release form of diltiazem
US5504117A (en) * 1994-05-27 1996-04-02 Neptune Pharmaceutical Corporation Pharmacologic preparation for the treatment of anal disorders

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2074627A1 (en) * 1970-01-13 1971-10-08 Socres Ppsoriasis treatment compsn
JPS6016917A (ja) * 1983-07-08 1985-01-28 Yamanouchi Pharmaceut Co Ltd 塩酸ニカルジピンまたはニフエジピンの軟膏剤
JPS60109519A (ja) * 1983-11-17 1985-06-15 Nippon Shinyaku Co Ltd ニフェジピン坐剤
US4931279A (en) 1985-08-16 1990-06-05 Bausch & Lomb Incorporated Sustained release formulation containing an ion-exchange resin
JPS63170316A (ja) 1986-12-30 1988-07-14 Fujimoto Seiyaku Kk ニフエジピン経皮吸収外用製剤
JPS63174924A (ja) * 1987-01-14 1988-07-19 Toko Yakuhin Kogyo Kk 軟膏基剤および軟膏剤
IT1222395B (it) * 1987-07-30 1990-09-05 Pierrel Spa Composizione farmaceutica per somministrazione intranasale comprendente l'ormone ghrh,un agonista colinergico e/o un sale biliare
BE1003002A6 (fr) 1989-03-21 1991-10-22 Coppe Jan Composition a mettre en oeuvre pour le traitement de la calvitie, et procedes faisant usage de celle-ci.
IL92952A (en) 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5534520A (en) 1990-04-10 1996-07-09 Fisher; Abraham Spiro compounds containing five-membered rings
JP3273785B2 (ja) * 1990-08-13 2002-04-15 ダブリュー． イェスエア，デービッド 薬物または熱源送達用混合脂質―重炭酸塩コロイド粒子
US5332576A (en) * 1991-02-27 1994-07-26 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
SE9102340D0 (sv) * 1991-08-13 1991-08-13 Astra Ab Pharmaceutical composition containing carbachol and othercholinergic substances
WO1995006466A1 (en) * 1993-09-01 1995-03-09 Koren Laboratories Pty. Limited Treatment of anorectal disorders
JPH07145061A (ja) 1993-11-25 1995-06-06 Sekisui Chem Co Ltd 経皮吸収製剤
PT1051972E (pt) 1994-05-27 2007-12-07 Strakan Internat Ltd Uma Socie Composição dadora de óxido nítrico para tratamento de distúrbios anais
US5654337A (en) * 1995-03-24 1997-08-05 II William Scott Snyder Topical formulation for local delivery of a pharmaceutically active agent
IT1297886B1 (it) 1997-02-28 1999-12-20 Carmine Antropoli Nifedipina per uso topico

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084281A (en) * 1989-02-14 1992-01-28 Dillon Richard S Method and solution for treating tissue wounds
US5162315A (en) * 1989-05-08 1992-11-10 Rajadhyaksha Vithal J Penetration enhancers
US5288505A (en) * 1991-06-26 1994-02-22 Galephar P.R., Inc., Ltd. Extended release form of diltiazem
US5504117A (en) * 1994-05-27 1996-04-02 Neptune Pharmaceutical Corporation Pharmacologic preparation for the treatment of anal disorders

Cited By (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
US9492412B2 (en) 2002-10-25 2016-11-15 Foamix Pharmaceuticals Ltd. Penetrating pharmaceutical foam
US8435498B2 (en) 2002-10-25 2013-05-07 Foamix Ltd. Penetrating pharmaceutical foam
US20070253911A1 (en) * 2002-10-25 2007-11-01 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US10821077B2 (en) 2002-10-25 2020-11-03 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US10322085B2 (en) 2002-10-25 2019-06-18 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9713643B2 (en) 2002-10-25 2017-07-25 Foamix Pharmaceuticals Ltd. Foamable carriers
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US20080317679A1 (en) * 2002-10-25 2008-12-25 Foamix Ltd. Foamable compositions and kits comprising one or more of a channel agent, a cholinergic agent, a nitric oxide donor, and related agents and their uses
US9622947B2 (en) 2002-10-25 2017-04-18 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US20060018937A1 (en) * 2002-10-25 2006-01-26 Foamix Ltd. Steroid kit and foamable composition and uses thereof
US11033491B2 (en) 2002-10-25 2021-06-15 Vyne Therapeutics Inc. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9539208B2 (en) 2002-10-25 2017-01-10 Foamix Pharmaceuticals Ltd. Foam prepared from nanoemulsions and uses
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9320705B2 (en) 2002-10-25 2016-04-26 Foamix Pharmaceuticals Ltd. Sensation modifying topical composition foam
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US8840869B2 (en) 2002-10-25 2014-09-23 Foamix Ltd. Body cavity foams
US8741265B2 (en) 2002-10-25 2014-06-03 Foamix Ltd. Penetrating pharmaceutical foam
US8722021B2 (en) 2002-10-25 2014-05-13 Foamix Ltd. Foamable carriers
US20060233721A1 (en) * 2002-10-25 2006-10-19 Foamix Ltd. Foam containing unique oil globules
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US8486375B2 (en) 2003-04-28 2013-07-16 Foamix Ltd. Foamable compositions
US8119106B2 (en) 2003-04-28 2012-02-21 Foamix Ltd Foamable iodine compositions
US9101662B2 (en) 2003-08-04 2015-08-11 Foamix Pharmaceuticals Ltd. Compositions with modulating agents
US8518378B2 (en) 2003-08-04 2013-08-27 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US20080206159A1 (en) * 2003-08-04 2008-08-28 Foamix Ltd. Compositions with modulating agents
US9636405B2 (en) 2003-08-04 2017-05-02 Foamix Pharmaceuticals Ltd. Foamable vehicle and pharmaceutical compositions thereof
US8703105B2 (en) 2003-08-04 2014-04-22 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US8362091B2 (en) 2003-08-04 2013-01-29 Foamix Ltd. Foamable vehicle and pharmaceutical compositions thereof
US8114385B2 (en) 2003-08-04 2012-02-14 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US20070280891A1 (en) * 2003-08-04 2007-12-06 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US9050253B2 (en) 2003-08-04 2015-06-09 Foamix Pharmaceuticals Ltd. Oleaginous pharmaceutical and cosmetic foam
US20060275218A1 (en) * 2003-08-04 2006-12-07 Foamix Ltd. Foamable vehicle and pharmaceutical compositions thereof
US20080152596A1 (en) * 2005-07-19 2008-06-26 Foamix Ltd. Polypropylene glycol foamable vehicle and pharmaceutical compositions thereof
US20100179151A1 (en) * 2006-08-16 2010-07-15 Bayer Animal Health Gmbh Transdermal application of triazines for controlling infections with coccidia
US8217062B2 (en) 2006-09-01 2012-07-10 Moberg Derma Ab Topical composition comprising a dihydropyridine calcium antagonist
US20100010052A1 (en) * 2006-09-01 2010-01-14 Moberg Derma Ab Topical composition comprising a dihydropyridine calcium antagonist
US20080206155A1 (en) * 2006-11-14 2008-08-28 Foamix Ltd. Stable non-alcoholic foamable pharmaceutical emulsion compositions with an unctuous emollient and their uses
US9682021B2 (en) 2006-11-14 2017-06-20 Foamix Pharmaceuticals Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US8795635B2 (en) 2006-11-14 2014-08-05 Foamix Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US20100221195A1 (en) * 2006-11-14 2010-09-02 Foamix Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US20080292560A1 (en) * 2007-01-12 2008-11-27 Dov Tamarkin Silicone in glycol pharmaceutical and cosmetic compositions with accommodating agent
US11103454B2 (en) 2007-08-07 2021-08-31 Vyne Therapeutics Inc. Wax foamable vehicle and pharmaceutical compositions thereof
US10369102B2 (en) 2007-08-07 2019-08-06 Foamix Pharmaceuticals Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US9662298B2 (en) 2007-08-07 2017-05-30 Foamix Pharmaceuticals Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
US9549898B2 (en) 2007-12-07 2017-01-24 Foamix Pharmaceuticals Ltd. Oil and liquid silicone foamable carriers and formulations
US8343945B2 (en) 2007-12-07 2013-01-01 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US20110212033A1 (en) * 2007-12-07 2011-09-01 Foamix Ltd. Oil and liquid silicone foamable carriers and formulations
US8518376B2 (en) 2007-12-07 2013-08-27 Foamix Ltd. Oil-based foamable carriers and formulations
US8900553B2 (en) 2007-12-07 2014-12-02 Foamix Pharmaceuticals Ltd. Oil and liquid silicone foamable carriers and formulations
US11433025B2 (en) 2007-12-07 2022-09-06 Vyne Therapeutics Inc. Oil foamable carriers and formulations
US9795564B2 (en) 2007-12-07 2017-10-24 Foamix Pharmaceuticals Ltd. Oil-based foamable carriers and formulations
US9161916B2 (en) 2007-12-07 2015-10-20 Foamix Pharmaceuticals Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US8709385B2 (en) 2008-01-14 2014-04-29 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
US10588858B2 (en) 2009-04-28 2020-03-17 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10363216B2 (en) 2009-04-28 2019-07-30 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US9884017B2 (en) 2009-04-28 2018-02-06 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10213384B2 (en) 2009-04-28 2019-02-26 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US9072667B2 (en) 2009-07-29 2015-07-07 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US10350166B2 (en) 2009-07-29 2019-07-16 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US11219631B2 (en) 2009-07-29 2022-01-11 Vyne Pharmaceuticals Inc. Foamable compositions, breakable foams and their uses
US10092588B2 (en) 2009-07-29 2018-10-09 Foamix Pharmaceuticals Ltd. Foamable compositions, breakable foams and their uses
US9167813B2 (en) 2009-07-29 2015-10-27 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US9572775B2 (en) 2009-07-29 2017-02-21 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US10517882B2 (en) 2009-10-02 2019-12-31 Foamix Pharmaceuticals Ltd. Method for healing of an infected acne lesion without scarring
US8618081B2 (en) 2009-10-02 2013-12-31 Foamix Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US10238746B2 (en) 2009-10-02 2019-03-26 Foamix Pharmaceuticals Ltd Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10265404B2 (en) 2009-10-02 2019-04-23 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US9675700B2 (en) 2009-10-02 2017-06-13 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10322186B2 (en) 2009-10-02 2019-06-18 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10213512B2 (en) 2009-10-02 2019-02-26 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10137200B2 (en) 2009-10-02 2018-11-27 Foamix Pharmaceuticals Ltd. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US10967063B2 (en) 2009-10-02 2021-04-06 Vyne Therapeutics Inc. Surfactant-free, water-free formable composition and breakable foams and their uses
US10463742B2 (en) 2009-10-02 2019-11-05 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10029013B2 (en) 2009-10-02 2018-07-24 Foamix Pharmaceuticals Ltd. Surfactant-free, water-free formable composition and breakable foams and their uses
US10086080B2 (en) 2009-10-02 2018-10-02 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US8865139B1 (en) 2009-10-02 2014-10-21 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US8992896B2 (en) 2009-10-02 2015-03-31 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10610599B2 (en) 2009-10-02 2020-04-07 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10821187B2 (en) 2009-10-02 2020-11-03 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US8945516B2 (en) 2009-10-02 2015-02-03 Foamix Pharmaceuticals Ltd. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10835613B2 (en) 2009-10-02 2020-11-17 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US8871184B2 (en) 2009-10-02 2014-10-28 Foamix Ltd. Topical tetracycline compositions
US10543201B2 (en) 2013-10-03 2020-01-28 David Wise Compositions and methods for treating pelvic pain and other conditions
US9700549B2 (en) 2013-10-03 2017-07-11 David Wise Compositions and methods for treating pelvic pain and other conditions
US10849847B2 (en) 2016-09-08 2020-12-01 Foamix Pharamaceuticals Ltd. Compositions and methods for treating rosacea and acne
US11324691B2 (en) 2016-09-08 2022-05-10 Journey Medical Corporation Compositions and methods for treating rosacea and acne
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
US11766428B2 (en) 2018-06-01 2023-09-26 Tavanta Therapeutics Hungary Incorporated Topical amlodipine salts for the treatment of anorectal diseases
RU2710742C1 (ru) * 2019-05-14 2020-01-10 Александра Александровна Савосина Композиция для лечения анальных трещин на основе фелодипина
WO2021118400A1 (ru) 2019-12-13 2021-06-17 Александр Евгеньевич БАРАННИКОВ Фармакологическая композиция для лечения проктологических заболеваний (варианты)

Also Published As

Publication number Publication date
DE69826644T2 (de) 2005-11-17
US20110263568A1 (en) 2011-10-27
PT969813E (pt) 2004-12-31
CN1127333C (zh) 2003-11-12
JP2002356422A (ja) 2002-12-13
CN1480139A (zh) 2004-03-10
US20130079332A1 (en) 2013-03-28
US8318721B2 (en) 2012-11-27
IL178133A0 (en) 2006-12-31
EP0969813A2 (en) 2000-01-12
CN1248162A (zh) 2000-03-22
EP0969813B1 (en) 2004-09-29
JP2001517210A (ja) 2001-10-02
AU733047B2 (en) 2001-05-03
EP1249238A2 (en) 2002-10-16
DE69826644D1 (de) 2004-11-04
AU6302498A (en) 1998-09-09
EP1249238A3 (en) 2003-03-26
AU733047C (en) 2002-05-16
DK0969813T3 (da) 2005-01-31
CA2281755C (en) 2006-11-07
US8906903B2 (en) 2014-12-09
CA2281755A1 (en) 1998-08-27
EP1250927A2 (en) 2002-10-23
CN100379423C (zh) 2008-04-09
WO1998036733A3 (en) 1998-11-26
EP1249238A8 (en) 2002-12-04
EP1250927A3 (en) 2003-03-26
CN1515261A (zh) 2004-07-28
ES2224362T3 (es) 2005-03-01
WO1998036733A2 (en) 1998-08-27
JP3352095B2 (ja) 2002-12-03
ATE277596T1 (de) 2004-10-15
IL131477A0 (en) 2001-01-28
JP2002356425A (ja) 2002-12-13

Similar Documents

Publication Publication Date Title
US8906903B2 (en) Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker
US4708873A (en) Method of chemically debriding uncerated necrotic tissue
JPH07196516A (ja) 痔疾患治療剤
US8048875B1 (en) Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker
AU758944B2 (en) Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker
AU2003203991B2 (en) Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker
RU2730483C1 (ru) Способ приготовления фармацевтической гелевой композиции для лечения проктологических заболеваний (варианты).
RU2733080C1 (ru) Фармакологическая композиция для лечения проктологических заболеваний (варианты).
CA2554085A1 (en) Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker
JP4306837B2 (ja) スクラルファート含有局所投与用医薬組成物
JP2005029529A (ja) 痔疾治療薬
WO2020260917A1 (en) Topical pharmaceutical compositions comprising diltiazem
US20140235570A1 (en) Therapeutic composition for the treatment of perianal disorders
US6897239B1 (en) Use of misoprostol and/or metabolites of misoprostol for treating sexual dysfunction in women
Rosenberg The use of corticosteroid ointments in the management of postoperative anorectal wounds
EP1700597A1 (en) Pharmaceutical composition containing in association ubidecarenone, dexpanthenol and chlorhexidine or a pharmaceutically acceptable salt thereof for cutaneous application
AU8833098A (en) Treatment of anorectal disorders
JPH0753383A (ja) 全身活性抗アンドロゲンであるスピロノラクトンの、皮膚を通しての投与方法並びに尋常性ざ瘡、脂漏性皮膚炎及び多毛症の局所治療のための製剤組成物

Legal Events

Date Code Title Description
AS Assignment

Owner name: S.L.A. PHARMA AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KAMM, MICHAEL A.;PHILLIPS, ROBIN K.S.;REEL/FRAME:020688/0001

Effective date: 20080211

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION